Email Alerts
RSS
Volume 41 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  CHINESE JOURNAL OF BURNS AND WOUNDS  > 2025  >  41(6): 543-551
Zhou Jiping, Lin Yuyi, Zhu Minfei, et al. Clinical effects of extracorporeal shock wave combined with complex decongestive therapy in the treatment of lower limb lymphedema after cervical cancer surgery[J]. CHINESE JOURNAL OF BURNS AND WOUNDS, 2025, 41(6): 543-551. Doi: 10.3760/cma.j.cn501225-20250205-00051
Citation: Zhou Jiping, Lin Yuyi, Zhu Minfei, et al. Clinical effects of extracorporeal shock wave combined with complex decongestive therapy in the treatment of lower limb lymphedema after cervical cancer surgery[J]. CHINESE JOURNAL OF BURNS AND WOUNDS, 2025, 41(6): 543-551. Doi: 10.3760/cma.j.cn501225-20250205-00051
shu

Clinical effects of extracorporeal shock wave combined with complex decongestive therapy in the treatment of lower limb lymphedema after cervical cancer surgery

doi: 10.3760/cma.j.cn501225-20250205-00051
  • 1.

    Department of Oncology Rehabilitation, Nan'ao People's Hospital, Dapeng New District of Shenzhen, Shenzhen 518000, China

  • 2.

    Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 511400, China

Funds:

General Program of National Natural Science Foundation of China 82272598

Guangdong Medical Research Foundation B2024008

Shenzhen Dapeng New District Medical and Health Group Research Project 2022JTYM04

More Information
    Abstract
  •   Objective  To explore the clinical effects of extracorporeal shock wave therapy (ESWT) combined with complex decongestive therapy (CDT) in the treatment of lower limb lymphedema after cervical cancer surgery.  Methods  This study was a prospective randomized controlled trial. From April 2023 to December 2024, 64 patients were admitted to the Department of Oncology Rehabilitation of Nan'ao People's Hospital of Dapeng New District of Shenzhen. All patients were female, aged 33-75 years. The patients were divided into control group treated with CDT alone and combined treatment group treated with ESWT and CDT according to the random number table method, with 32 patients in each group. Four patients withdrew in the research process, and 30 patients were included in each group finally. Before treatment and at the end of 4 weeks of treatment (hereinafter referred to as after treatment), the skin stiffness was measured using a portable MyotonPRO device at the superficial projection position of vastus lateralis, vastus medialis, vastus intermedius, medial gastrocnemius, and lateral gastrocnemius to reflect the degree of skin fibrosis of lower limb, the circumferences were measured at the mid-knee, 10 cm and 20 cm above the superior patellar border, and the mid-ankle, 10 cm and 20 cm below the inferior patellar border to reflect the severity degree of edema of lower limb, the life quality was scored using the simplified Chinese version of the lower limb lymphedema functioning, disability, and health questionnaire (Lymph-ICF-LL), and the pain intensity was scored using the visual analogue scale (VAS). The differences of the above indexes were calculated between before and after treatment.  Results  The skin stiffness at the superficial projection position of vastus lateralis, vastus medialis, vastus intermedius, medial gastrocnemius, and lateral gastrocnemius of patients in combined treatment group after treatment was significantly smaller than that in control group (with t values of 2.78, 2.04, 3.12, 2.01, and 2.35, respectively, P < 0.05). The differences in skin stiffness between before and after treatment at the superficial projection position of the above-mentioned muscles of patients in combined treatment group was (65±23), (24±8), (25±8), (65±27), and (69±34) N/m, respectively, which were significantly larger than (49±23), (16±19), (8±9), (45±39), and (43±42) N/m in control group (with t values of -2.75 -2.35, -7.47, -2.33, and -2.64, respectively, P < 0.05), and the mean differences between groups (95% confidence intervals) were 16 (5 to 28), 9 (1 to 17), 17 (12 to 21), 20 (3 to 36), and 26 (4 to 49) N/m, respectively. The circumferences at 10 cm and 20 cm below the inferior patellar border, mid-knee, and 10 cm and 20 cm above the superior patellar border of patients in combined treatment group after treatment were significantly smaller than those in control group (with t values of -2.41, -2.49, -2.44, -2.21, and -2.36, respectively, P < 0.05). The circumference differences between before and after treatment at the above-mentioned locations of patients in combined treatment group were significantly larger than those in control group (with t values of 2.21, 3.62, 3.35, 4.14, and 3.89, respectively, P < 0.05), and the mean differences between groups (95% confidence intervals) were 2.3 (0.1 to 4.6), 2.4 (1.0 to 3.8), 2.1 (0.8 to 3.4), 3.5 (1.6 to 5.4), and 3.4 (1.5 to 5.2) cm, respectively. The VAS scores of lower limb and the total Lymph-ICF-LL scores of patients in combined treatment group after treatment were significantly lower than those in control group (with t values of -2.46 and -2.63, respectively, P < 0.05); the differences of VAS scores of lower limb and the total Lymph-ICF-LL scores between before and after treatment of patients in combined treatment group were significantly higher than those in control group (with t values of 2.34 and 3.32, respectively, P < 0.05), and the mean differences between groups (95% confidence intervals) were 0.5 (0 to 0.9) and 6 (2 to 9), respectively.  Conclusions  Combined application of ESWT and CDT shows superior efficacy in alleviating lower limb lymphedema and skin fibrosis after cervical cancer surgery, and can relieve pain and improve patients' quality of life.

     

    • A prospective randomized controlled trial was conducted and confirmed that extracorporeal shock wave therapy (ESWT) combined with complex decongestive therapy could significantly mitigate edema and skin fibrosis in patients with lower limb lymphedema after cervical cancer surgery and improve their quality of life. As a non-invasive, innovative, and efficacious treatment modality, ESWT provided a highly promising treatment option for this chronic, progressive, and refractory disease.
    FullText(HTML)
  • loading
    • References(40)
  • [1]
    刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J/OL]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13[2025-02-05]. http://www.jmcm2018.com/CN/10.12151/JMCM.2021.02-01. DOI: 10.12151/JMCM.2021.02-01.
    [2]
    Dayan JH, Ly CL, Kataru RP, et al. Lymphedema: pathogenesis and novel therapies[J]. Annu Rev Med, 2018, 69(1): 263-276. DOI: 10.1146/annurev-med-060116-022900.
    [3]
    Lee KW, Kim SB, Lee JH, et al. Effects of extracorporeal shockwave therapy on improvements in lymphedema, quality of life, and fibrous tissue in breast cancer-related lymphedema[J]. Ann Rehabil Med, 2020, 44(5): 386-392. DOI: 10.5535/arm.19213.
    [4]
    Auersperg V, Trieb K. Extracorporeal shock wave therapy: an update[J]. EFORT Open Rev, 2020, 5(10): 584-592. DOI: 10.1302/2058-5241.5.190067.
    [5]
    廖冬发, 权毅, 潘显明, 等. 体外冲击波治疗部队伤病员末端病疗效观察[J]. 解放军医学杂志, 2009, 34(6): 806. DOI: 10.3321/j.issn:0577-7402.2009.06.054.
    [6]
    傅聪颖, 黎宁, 李茂君, 等. 非药物干预治疗患者慢性创面疼痛效果的系统评价与贝叶斯网状荟萃分析[J]. 中华烧伤与创面修复杂志, 2025, 41(5): 491-500. DOI: 10.3760/cma.j.cn501225-20241213-00486.
    [7]
    Miccinilli S, Bravi M, Maselli M, et al. The effectiveness of extracorporeal shock wave therapy on breast cancer-related lymphedema: a literature review[J]. Lymphology, 2020, 53(3): 118-135.
    [8]
    Tsai YL, I TJ, Chuang YC, et al. Extracorporeal shock wave therapy combined with complex decongestive therapy in patients with breast cancer-related lymphedema: a systemic review and meta-analysis[J]. J Clin Med, 2021, 10(24): 5970. DOI: 10.3390/jcm10245970.
    [9]
    Lee JH, Kim SB, Lee KW, et al. Long-term effects of extracorporeal shock wave therapy on breast cancer-related lymphedema[J]. J Clin Med, 2022, 11(22): 6747. DOI: 10.3390/jcm11226747.
    [10]
    谢幸, 孔北华, 段涛. 妇产科学[M]. 9版. 北京: 人民卫生出版社, 2018.
    [11]
    Executive Committee of the International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2023 Consensus Document of The International Society of Lymphology[J]. Lymphology, 2023, 56(4): 133-151.
    [12]
    周煦川, 马戈甲, 王文飞, 等. 简体中文版下肢淋巴水肿功能、残疾与健康问卷的信度和效度分析[J]. 中华整形外科杂志, 2023, 39(6): 634-641. DOI: 10.3760/cma.j.cn114453-20220309-00060.
    [13]
    Bona AF, Ferreira KR, Carvalho RBM, et al. Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review[J]. Int J Gynecol Cancer, 2020, 30(11): 1697-1704. DOI: 10.1136/ijgc-2020-001682.
    [14]
    Finnane A, Janda M, Hayes SC. Review of the evidence of lymphedema treatment effect[J]. Am J Phys Med Rehabil, 2015, 94(6): 483-498. DOI: 10.1097/PHM.0000000000000246.
    [15]
    黄成, 胡学庆. 淋巴水肿治疗的研究进展[J]. 组织工程与重建外科, 2022, 18 (1): 38-41. DOI: 10.3969/j.issn.1673-0364.2022.01.009.
    [16]
    Carroll BJ, Singhal D. Advances in lymphedema: an under-recognized disease with a hopeful future for patients [J]. Vasc Med, 2024, 29(1): 70-84. DOI: 10.1177/1358863X231215329.
    [17]
    Zhang HZ, Zhong QL, Zhang HT, et al. Effectiveness of six-step complex decongestive therapy for treating upper limb lymphedema after breast cancer surgery[J]. World J Clin Cases, 2022, 10(25): 8827-8836. DOI: 10.12998/wjcc.v10.i25.8827.
    [18]
    Zeng Y, Liu G, Peng Z, et al. Application of complete decongestive therapy in patients with secondary bilateral lower limb lymphedema after comprehensive treatment of gynecological malignant tumor[J]. Lymphat Res Biol, 2024, 22(1): 60-65. DOI: 10.1089/lrb.2023.0029.
    [19]
    Thompson B, Gaitatzis K, Janse de Jonge X, et al. Manual lymphatic drainage treatment for lymphedema: a systematic review of the literature[J]. J Cancer Surviv, 2021, 15(2): 244-258. DOI: 10.1007/s11764-020-00928-1.
    [20]
    陈佳佳, 高敏哲, 汪立, 等. 妇科相关肿瘤术后下肢淋巴水肿合并会阴部水肿的综合治疗初探[J]. 组织工程与重建外科杂志, 2022, 18(3): 242-246. DOI: 10.3969/j.issn.1673-0364.2022.03.008.
    [21]
    Chen F, Dellalana LE, Gandelman JS, et al. Non-invasive measurement of sclerosis in cutaneous cGVHD patients with the handheld device Myoton: a cross-sectional study [J]. Bone Marrow Transplant, 2019, 54(4): 616-619. DOI: 10.1038/s41409-018-0346-7.
    [22]
    John AJUK, Galdo FD, Gush R, et al. An evaluation of mechanical and biophysical skin parameters at different body locations[J]. Skin Res Technol, 2023, 29(2): e13292. DOI: 10.1111/srt.13292.
    [23]
    Junker HJ, Thumm B, Halvachizadeh S, et al. A quantitative comparison of devices for in vivo biomechanical characterization of human skin[J]. Mech Soft Mater, 2023, 5(1): 5. DOI: 10.1007/s42558-023-00053-w.
    [24]
    Glassman GE, Dellalana L, Tkaczyk ER, et al. Measuring biomechanical properties using a noninvasive Myoton device for lymphedema detection and tracking: a pilot study[J]. Eplasty, 2022, 22: e54.
    [25]
    Dellalana LE, Chen F, Vain A, et al. Reproducibility of the durometer and myoton devices for skin stiffness measurement in healthy subjects[J]. Skin Res Technol, 2019, 25(3): 289-293. DOI: 10.1111/srt.12646.
    [26]
    Lettner J, Królikowska A, Ramadanov N, et al. Evaluating the reliability of MyotonPro in assessing muscle properties: a systematic review of diagnostic test accuracy[J]. Medicina (Kaunas), 2024, 60(6): 851. DOI: 10.3390/medicina60060851.
    [27]
    Lin YP, Huang HY, Wu MH, et al. Effects of extracorporeal shock wave therapy on motor recovery, arm circumference, subcutaneous tissue thickness and skin thickness in a case with breast cancer related lymphedema portrayed with sonographic technique[J]. Rehabil Pract Sci, 2023, 1: 49-56.
    [28]
    Grushina TI, Orlov II. Pilot study of oncological safety of extracorporeal shock wave therapy for post-mastectomy lymphedema in patients with breast cancer[J]. Vopr Kurortol Fizioter Lech Fiz Kult, 2022, 99(6): 30-33. DOI: 10.17116/kurort20229906130.
    [29]
    Kojima M, Yamauchi C, Oyamada S, et al. Assessment of upper limb physiological features in patients with lymphedema after breast surgery using multiple instruments[J]. Lymphat Res Biol, 2020, 18(3): 239-246. DOI: 10.1089/lrb.2019.0039.
    [30]
    Cui HS, Joo SY, Cho YS, et al. Effect of extracorporeal shock wave therapy on keratinocytes derived from human hypertrophic scars[J]. Sci Rep, 2021, 11(1): 17296. DOI: 10.1038/s41598-021-96537-8.
    [31]
    Simplicio CL, Purita J, Murrell W, et al. Extracorporeal shock wave therapy mechanisms in musculoskeletal regenerative medicine[J]. J Clin Orthop Trauma, 2020, 11(Suppl 3): S309-318. DOI: 10.1016/j.jcot.2020.02.004.
    [32]
    陈伟, 徐广超, 黄仲路, 等. 神经再生相关蛋白在皮肤纤维化中的作用机制研究进展[J]. 中华烧伤与创面修复杂志, 2023, 39(5): 491-495. DOI: 10.3760/cma.j.cn501225-20220701-00278.
    [33]
    Cebicci MA, Sutbeyaz ST, Goksu SS, et al. Extracorporeal shock wave therapy for breast cancer-related lymphedema: a pilot study[J]. Arch Phys Med Rehabil, 2016, 97(9): 1520-1525. DOI: 10.1016/j.apmr.2016.02.019.
    [34]
    Planas-Paz L, Lammert E. Mechanical forces in lymphatic vascular development and disease[J]. Cell Mol Life Sci, 2013, 70(22): 4341-4354. DOI: 10.1007/s00018-013-1358-5.
    [35]
    Wang M, Yang D, Hu Z, et al. Extracorporeal cardiac shock waves therapy improves the function of endothelial progenitor cells after hypoxia injury via activating PI3K/ Akt/eNOS signal pathway[J]. Front Cardiovasc Med, 2021, 8: 747497. DOI: 10.3389/fcvm.2021.747497.
    [36]
    Cho HK, Sung WJ, Lee YJ, et al. Two methods of extracorporeal shock-wave therapy in a rat model of secondary lymphedema: a pilot study[J]. J Int Med Res, 2021, 49(6): 3000605211024473. DOI: 10.1177/03000605211024473.
    [37]
    Lee SO, Kim IK. Molecular pathophysiology of secondary lymphedema[J]. Front Cell Dev Biol, 2024, 12: 1363811. DOI: 10.3389/fcell.2024.1363811.
    [38]
    Serizawa F, Ito K, Matsubara M, et al. Extracorporeal shock wave therapy induces therapeutic lymphangiogenesis in a rat model of secondary lymphoedema[J]. Eur J Vasc Endovasc Surg, 2011, 42(2): 254-260. DOI: 10.1016/j.ejvs.2011.02.029.
    [39]
    Kubo M, Li TS, Kamota T, et al. Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis[J]. J Vasc Surg, 2010, 52(2): 429-434. DOI: 10.1016/j.jvs.2010.03.017.
    [40]
    Bae H, Kim HJ. Clinical outcomes of extracorporeal shock wave therapy in patients with secondary lymphedema: a pilot study[J]. Ann Rehabil Med, 2013, 37(2): 229-234. DOI: 10.5535/arm.2013.37.2.229.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (897) PDF downloads(16) Cited by()
    Proportional views
    Related

    Copyright © Chinese Journal of Burns京ICP备07035254号-14

    E-mail：shaoshangzazhi@163.com

    Website：https://zhsszz.xml-journal.net/

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return